Astellas Pharma, Dyno Therapeutics Partner on Potential $1.6 Billion Licensing Deal
PRESS RELEASE — Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced a license agreement to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno’s CapsidMap™ platform. Under the terms of the agreement, Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Astellas will …
Astellas Pharma, Dyno Therapeutics Partner on Potential $1.6 Billion Licensing Deal Read More »